Hippocratic AI raises USD 141M Series B round

Hippocratic AI logo

Hippocratic AIIndependently confirmed

$141M Series B

Hippocratic AI rolls out an AI agent app store.

Announced
2025-01-09
Stage
Series B
Category
Health App

The round

Hippocratic AI, a health app company, has announced a Series B funding round totaling USD 141.0 million. This investment propels the company into “unicorn” status, reaching a valuation of $1.64 billion. The funding round was led by venture capital firm Kleiner Perkins. Other investors participating in the Series B round include General Catalyst, Andreessen Horowitz (a16z), Nvidia, Premji, SV Angel, UHS, and WellSpan Health. This significant capital injection comes only nine months after Hippocratic AI’s Series A round, bringing the company’s total funding from investors to $278 million.

What Hippocratic AI does

Hippocratic AI is focused on leveraging artificial intelligence to address the global shortage of healthcare staffing. The company develops a large language model specifically tailored for healthcare applications. Its core offering includes a staffing marketplace where health systems, payers, and other organizations can utilize generative-AI-powered agents. These agents are designed to perform low-risk, non-diagnostic, patient-facing services, such as chronic care management and post-discharge follow-ups for specific conditions like congestive heart failure and kidney disease. Hippocratic AI recently rolled out an AI agent app store, which allows clinicians to collaborate in designing and shaping AI agents to tackle patient care and operational challenges.

Since emerging from stealth in May 2023, Hippocratic AI has rapidly expanded. Key milestones include raising a $53 million Series A in March, followed by a $17 million investment from Nvidia. The company has also released its first commercial product, a generative AI-based, task-specific healthcare agent, and introduced its Polaris 2.0 architecture. Hippocratic AI has expanded its advisory councils to include nurses, physicians, and industry experts, and has secured its first U.S. patent. The company reports achieving safety parity between its AI agents and human clinicians. By 2024, Hippocratic AI had secured partnerships with 23 healthcare organizations, deployed agents for 16 clients, and completed over 200,000 patient interactions, achieving an average satisfaction rating of 8.7 out of 10. Its proprietary Polaris architecture, scaled to 3.7 trillion parameters, underpins its safety and reliability standards.

What the funding will do

The newly secured capital is earmarked to fuel Hippocratic AI’s expansion beyond U.S. borders. The company plans to extend its reach into Europe, the Middle East, Africa, Southeast Asia, and Latin America. Additionally, the funding will support the company’s efforts to broaden its services into the pharmaceutical and insurance sectors, augmenting its existing suite of offerings that include preoperative care, chronic care management, and wellness coaching.

Why it matters

This funding round for Hippocratic AI highlights the growing investment and interest in AI solutions for the healthcare sector, particularly those addressing staffing shortages. The company’s focus on patient-facing, non-diagnostic AI agents represents a significant development in how technology can augment healthcare delivery. By enabling clinicians to design and shape AI agents, Hippocratic AI aims to create scalable solutions that can alleviate the burden on human healthcare professionals and potentially increase access to care globally. The rapid valuation increase and the participation of prominent investors underscore the perceived impact and potential of AI in transforming healthcare operations and patient interactions.

This record aggregates public reporting and filings. Figures are verified against the sources listed above; USD figures use the announcement-date exchange rate.